Medical treatment quality control

A patient deserves to know what he or she is taking. When a person acquires a medication at a healthcare center, they need to be confident that they are protected from fraudulent, low-quality, and even dangerous products. As a developer and manufacturer of high quality, effective medical treatments, New Vision Solutions is committed to ensuring the safety of our pharmaceutical products and their quality assurance. Our expertise - and the cooperation of State agencies - allows us to establish reference quality control laboratories, fully equipped to comply with EU GLP requirements. We supplement existing practices of finished product control by further monitoring of manufacturing conditions, using larger control batches, and a number of other extensive measures to ensure consumer safety.

Every person in every country deserves quality assurance and the safety and efficacy of medical treatment. This is a universal right. Patients must expect protection from:

  • Ingredients which do not conform to their product labeling, potentially dispensing life- threatening medications;
  • Insufficiency or absence of the active substance in a medication;
  • Presence of foreign substances and pathogens;
  • Medications produced in unsterile or microbiologically compromised conditions;
  • Presence of bacterial endotoxins and other toxins.

As a developer and manufacturer of high quality, effective medical treatments, New Vision Solutions is committed to ensuring the safety of our pharmaceutical products and their quality assurance. Our expertise - and the cooperation of State agencies - allows us to establish reference quality control laboratories, fully equipped to comply with EU GLP requirements.

The framework of quality assurance involves:

  • modern reference laboratories equipped in accordance with international standards, and possessing advanced technological capacity satisfying international requirements;
  • the audit and accreditation of quality control laboratories within a European network;
  • supplementing final product control practices by further monitoring of manufacturing conditions;
  • utilizing larger selective control batches.